Lytix Biopharma ASA (FRA:6BG)

Market Cap	55.45M +2.7%
Revenue (ttm)	n/a
Net Income	-6.50M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.6900
Previous Close	0.6820
Day's Range	0.6900 - 0.6900
52-Week Range	0.5680 - 1.0150
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Lytix Biopharma ASA

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as he...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 14
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6BG

Financial Performance

Financial numbers in NOK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error